MA33585B1 - Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée - Google Patents

Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée

Info

Publication number
MA33585B1
MA33585B1 MA34687A MA34687A MA33585B1 MA 33585 B1 MA33585 B1 MA 33585B1 MA 34687 A MA34687 A MA 34687A MA 34687 A MA34687 A MA 34687A MA 33585 B1 MA33585 B1 MA 33585B1
Authority
MA
Morocco
Prior art keywords
trifluoromethylphenyl
cyano
hydroxy
enoic acid
improved stability
Prior art date
Application number
MA34687A
Other languages
English (en)
Inventor
Gerrit Hauck
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41510564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33585(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33585B1 publication Critical patent/MA33585B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSITIONS PHARMACEUTIQUES SOLIDES COMPRENANT DU (4'-TRIFLUOROMÉTHYLPHÉNYL)-AMIDE DE L'ACIDE (Z)-2-CYANO-3-HYDROXY-BUT-2-ÉNOÏQUE, AINSI QUE LEUR PROCÉDÉ DE PRÉPARATION, DES PROCÉDÉS D'UTILISATION DE TELLES COMPOSITIONS POUR TRAITER DES SUJETS SOUFFRANT DE MALADIES AUTO-IMMUNES, NOTAMMENT DE LUPUS ÉRYTHÉMATEUX SYSTÉMIQUE OU DE RÉACTIONS CHRONIQUES DE GREFFE CONTRE L'HÔTE, DE SCLÉROSE EN PLAQUES OU D'ARTHRITE RHUMATOÏDE.
MA34687A 2009-09-18 2012-03-13 Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée MA33585B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290716 2009-09-18
US36338210P 2010-07-12 2010-07-12
PCT/EP2010/063439 WO2011032929A1 (fr) 2009-09-18 2010-09-14 Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée

Publications (1)

Publication Number Publication Date
MA33585B1 true MA33585B1 (fr) 2012-09-01

Family

ID=41510564

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34687A MA33585B1 (fr) 2009-09-18 2012-03-13 Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée

Country Status (42)

Country Link
US (5) US20120172427A1 (fr)
EP (1) EP2477611B1 (fr)
JP (1) JP2013505213A (fr)
KR (1) KR101547880B1 (fr)
CN (4) CN104666272A (fr)
AR (1) AR078383A1 (fr)
AU (2) AU2010297357B2 (fr)
BR (1) BR112012006184B1 (fr)
CA (1) CA2772275A1 (fr)
CL (1) CL2015000047A1 (fr)
CO (1) CO6511244A2 (fr)
CR (2) CR20170078A (fr)
CY (1) CY1119364T1 (fr)
DK (1) DK2477611T3 (fr)
DO (1) DOP2012000070A (fr)
ES (1) ES2625731T3 (fr)
GT (1) GT201200075A (fr)
HK (1) HK1206244A1 (fr)
HN (1) HN2012000576A (fr)
HR (1) HRP20170904T1 (fr)
HU (1) HUE032963T2 (fr)
IL (3) IL218492A (fr)
JO (1) JO3327B1 (fr)
LT (1) LT2477611T (fr)
MA (1) MA33585B1 (fr)
ME (1) ME02765B (fr)
MX (1) MX336663B (fr)
MY (1) MY155613A (fr)
NZ (2) NZ598744A (fr)
PE (2) PE20152031A1 (fr)
PL (1) PL2477611T3 (fr)
PT (1) PT2477611T (fr)
PY (1) PY1038455A (fr)
RS (1) RS56074B1 (fr)
RU (2) RU2681079C2 (fr)
SI (1) SI2477611T1 (fr)
SM (1) SMT201700299T1 (fr)
TN (1) TN2012000061A1 (fr)
TW (2) TWI468190B (fr)
UA (2) UA107582C2 (fr)
UY (1) UY32889A (fr)
WO (1) WO2011032929A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598744A (en) * 2009-09-18 2013-11-29 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
RU2493845C1 (ru) * 2012-06-07 2013-09-27 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Композиция для лечения рассеянного склероза (варианты)
EP3071199A2 (fr) * 2013-11-22 2016-09-28 Genzyme Corporation Nouvelles méthodes pour traiter des maladies neurodégénératives
CN103656657A (zh) * 2013-12-18 2014-03-26 北京科源创欣科技有限公司 特立氟胺药物组合物及制备方法
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
US20160058730A1 (en) * 2014-08-29 2016-03-03 Cadila Healthcare Limited Pharmaceutical compositions of teriflunomide
WO2016079687A1 (fr) * 2014-11-18 2016-05-26 Lupin Limited Composition pharmaceutique orale de tériflunomide
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US20180147148A1 (en) 2015-05-23 2018-05-31 Ftf Pharma Private Limited Pharmaceutical composition of teriflunomide
US11096934B2 (en) 2015-09-01 2021-08-24 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
WO2017037645A1 (fr) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Formulations pharmaceutiques stables de tériflunomide
WO2017056104A1 (fr) * 2015-09-28 2017-04-06 Natco Pharma Limited Compositions pharmaceutiques stables de tériflunomide
WO2017125841A1 (fr) * 2016-01-20 2017-07-27 Emcure Pharmaceuticals Limited Compositions pharmaceutiques de tériflunomide
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
RS65302B1 (sr) * 2019-07-17 2024-04-30 Cytokinetics Inc Oralne formulacije inhibitora srčanog sarkomera
DK4178548T3 (da) * 2020-07-07 2024-08-19 Celgene Corp Farmaceutiske sammensætninger omfattende (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUORBENZONITRIL
WO2022085015A1 (fr) * 2020-10-24 2022-04-28 V-Ensure Pharma Technologies Private Limited Composition orale solide de tériflunomide
GR1010137B (el) 2020-12-15 2021-12-07 Φαρματεν Α.Β.Ε.Ε., Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης
TR202022336A2 (tr) * 2020-12-30 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising teriflunomide
EP4382097A1 (fr) 2022-11-25 2024-06-12 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé comprenant du tériflunomide
TR2022017840A1 (tr) * 2022-11-25 2024-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Teri̇flunomi̇d i̇çeren bi̇r tablet

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852294A (en) * 1968-08-27 1974-12-03 Merck Patent Gmbh Bis-quaternary pyridinium salts
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US6133301A (en) 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
ATE194912T1 (de) 1994-10-17 2000-08-15 Aventis Pharma Ltd Mittel zur vorsorge und heilung von typ i allergischen krankheiten
EP0903345B1 (fr) 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Forme cristalline de N-(4-trifluorométhylphényl)-5-méthylisoxazole-4-carboxamid
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ES2237553T3 (es) 2000-02-15 2005-08-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la sintesis de leflunomida.
EP1381356B1 (fr) 2001-04-05 2008-05-28 Aventis Pharmaceuticals Inc. Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US20050158371A1 (en) 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
DE602004031134D1 (de) * 2003-08-29 2011-03-03 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
GB2394660A (en) 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
US20050220874A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
AU2005295511A1 (en) * 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
TWI275029B (en) * 2005-11-18 2007-03-01 Hon Hai Prec Ind Co Ltd An embedded system and method for processing data thereof
EP1810676B1 (fr) 2006-01-24 2008-11-12 Teva Pharmaceutical Industries Limited Formulations de Levetiracetam et méthodes pour leur fabrication
DE102006017896A1 (de) 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
EP1990048A3 (fr) 2007-05-08 2009-05-06 Ulrike Wiebelitz Thérapie pour l'hyperplasie bénigne de la prostate
NZ598744A (en) * 2009-09-18 2013-11-29 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
EP2762135A1 (fr) * 2013-02-04 2014-08-06 Sanofi Procédés permettant de réduire le risque d'une interaction de la rosuvastatine et du tériflunomide indésirable chez des patients atteints de sclérose en plaques

Also Published As

Publication number Publication date
CN104666238B (zh) 2018-04-06
RS56074B1 (sr) 2017-10-31
HN2012000576A (es) 2015-01-26
IL218492A (en) 2016-04-21
AU2013257516B2 (en) 2015-09-17
TWI522130B (zh) 2016-02-21
RU2681079C2 (ru) 2019-03-04
SI2477611T1 (sl) 2017-07-31
IL218492A0 (en) 2012-04-30
WO2011032929A1 (fr) 2011-03-24
RU2012115459A (ru) 2013-10-27
TW201117838A (en) 2011-06-01
BR112012006184A2 (pt) 2016-05-31
AU2010297357A1 (en) 2012-04-05
ES2625731T3 (es) 2017-07-20
PE20152031A1 (es) 2016-01-14
US20190241505A1 (en) 2019-08-08
KR20120089461A (ko) 2012-08-10
MX336663B (es) 2016-01-27
LT2477611T (lt) 2017-06-26
EP2477611B1 (fr) 2017-04-05
TW201517935A (zh) 2015-05-16
CN104666272A (zh) 2015-06-03
US20120208880A1 (en) 2012-08-16
CN102596184A (zh) 2012-07-18
CN102596184B (zh) 2015-03-11
EP2477611A1 (fr) 2012-07-25
CN104739821B (zh) 2018-04-06
AU2010297357B2 (en) 2013-11-07
IL244809B (en) 2019-03-31
CL2015000047A1 (es) 2015-06-12
CN104666238A (zh) 2015-06-03
TWI468190B (zh) 2015-01-11
SMT201700299T1 (it) 2017-07-18
MX2012003122A (es) 2012-04-10
IL244809A0 (en) 2016-04-21
MY155613A (en) 2015-11-13
UY32889A (es) 2011-04-29
PL2477611T3 (pl) 2017-09-29
KR101547880B1 (ko) 2015-08-27
AR078383A1 (es) 2011-11-02
ME02765B (fr) 2018-01-20
PE20121478A1 (es) 2012-11-12
US20120172427A1 (en) 2012-07-05
PY1038455A (es) 2014-07-01
DOP2012000070A (es) 2012-05-31
IL264912B (en) 2019-11-28
RU2015151938A3 (fr) 2019-01-15
CR20170078A (es) 2017-05-22
US20140235888A1 (en) 2014-08-21
US8802735B2 (en) 2014-08-12
HUE032963T2 (en) 2017-11-28
CA2772275A1 (fr) 2011-03-24
HK1206245A1 (en) 2016-01-08
TN2012000061A1 (en) 2013-09-19
DK2477611T3 (en) 2017-07-10
UA107582C2 (uk) 2015-01-26
GT201200075A (es) 2014-05-14
CN104739821A (zh) 2015-07-01
CO6511244A2 (es) 2012-08-31
JO3327B1 (ar) 2019-03-13
CR20120116A (es) 2012-06-15
NZ598744A (en) 2013-11-29
JP2013505213A (ja) 2013-02-14
HRP20170904T1 (hr) 2017-09-08
HK1206244A1 (en) 2016-01-08
CY1119364T1 (el) 2018-02-14
RU2015151938A (ru) 2019-01-15
UA115979C2 (uk) 2018-01-25
US20170247319A1 (en) 2017-08-31
NZ617025A (en) 2014-03-28
PT2477611T (pt) 2017-06-05
BR112012006184B1 (pt) 2022-10-18

Similar Documents

Publication Publication Date Title
MA33585B1 (fr) Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée
Alaskhar Alhamwe et al. Histone modifications and their role in epigenetics of atopy and allergic diseases
Zhong et al. Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications
Archambault et al. Comparison of eight 15-lipoxygenase (LO) inhibitors on the biosynthesis of 15-LO metabolites by human neutrophils and eosinophils
AU2011293135A8 (en) Pharmaceutical composition and administrations thereof
MX2009005398A (es) Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
WO2013185112A8 (fr) Compositions pharmaceutiques pour le traitement des troubles à médiation par cftr
Hu et al. Toll-like receptor 4 is a master regulator for colorectal cancer growth under high-fat diet by programming cancer metabolism
MA41654B2 (fr) Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
EP3552607A3 (fr) Inhibiteurs de syk d'imidazopyrazine
EA200802167A1 (ru) Лекарства и применения
MA33566B1 (fr) Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux
MX350010B (es) Inhibidores syk de imidazopiridinas.
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
Xu et al. Inhibition of the tyrosine phosphatase STEP61 restores BDNF expression and reverses motor and cognitive deficits in phencyclidine-treated mice
Kwiecińska et al. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells
Qadir et al. Epigenetic modification related to acetylation of histone and methylation of DNA as a key player in immunological disorders
Das et al. Antineoplastics for treating Alzheimer's disease and dementia: Evidence from preclinical and observational studies
Gu et al. β-Nicotinamide mononucleotide supplementation prolongs the lifespan of prematurely aged mice and protects colon function in ageing mice
Spugnini et al. Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma